Altria Releases Financial Report for Q4 2023 and Full Year, Net Revenue Reaching $24.48 Billion for 2023

Business by 2FIRSTS.ai
Feb.02.2024
Altria Releases Financial Report for Q4 2023 and Full Year, Net Revenue Reaching $24.48 Billion for 2023
Tobacco company Altschuyler reported a 2.2% decrease in Q4 and 2.4% decrease in full-year net revenues for 2023.

Altria Corporation, the official website, recently released its financial report for the fourth quarter and full year of 2023.

 

Altriai's net revenue in the fourth quarter of 2023 amounted to $5.98 billion, with a total net revenue of $24.48 billion for the entire fiscal year. This represents a decrease of 2.2% and 2.4% compared to the same period in 2022, respectively. The adjusted earnings per share for the fourth quarter remained unchanged at $1.18, as compared to the previous year.

 

According to a report released by ABC Company, the overall decline in net income was primarily attributed to a decrease in the revenue of the combustible tobacco products division. This decrease partially offset the increase in net income observed in the oral tobacco products division.

 

Ocheria expects its adjusted earnings per share for the full year of 2024 to be within the range of $5.00 to $5.15. This represents a growth rate of 1% to 4% compared to the baseline of $4.95 in 2023.

 

Billy Gifford, Chief Executive Officer of Orchia, has stated that electronic vaping products continue to be the most popular smoke-free products, with a growth of approximately 35% last year. However, a significant portion of this growth comes from illegally flavored disposable products, which account for half of the market share. Gifford stated, "The current state of the market is unacceptable for both legitimate manufacturers and consumers. These products are distributed by companies that have violated almost all regulations and guidelines issued by the US Food and Drug Administration since 2016.

 

Investors should take note that Altriai has enhanced shareholder returns through share buybacks and dividend payments.

 

In 2023, Ochiya repurchased 22.7 million shares at an average price of $43.96, returning $1 billion in cash to shareholders. The company's board of directors has now authorized a new $1 billion stock repurchase plan, expected to be completed by the end of 2024.

 

In August of last year, AAltria increased its dividend by 4.3%, marking the 58th dividend growth in the past 54 years. According to the financial report, dividends paid in the fourth quarter amounted to $1.7 billion, while dividends projected for 2023 are estimated at $6.8 billion.

 

In 2018, Altria acquired a 35% stake in e-cigarette company JUUL Labs for a total investment of $12.8 billion. However, the company faced legal challenges related to youth smoking as JUUL was accused of aggressively targeting the teenage market.

 

As of the end of 2022, Altria's valuation of JUUL has plummeted to only $250 million.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Fifth Circuit Hears Challenge to FDA’s Standard for Reviewing Flavored Vape Applications
Fifth Circuit Hears Challenge to FDA’s Standard for Reviewing Flavored Vape Applications
A three-judge panel of the U.S. Court of Appeals for the Fifth Circuit heard oral arguments on Tuesday in a case brought by seven small vape-liquid companies challenging the Food and Drug Administration’s denial of marketing authorization for their flavored electronic nicotine products.
Apr.30 by 2FIRSTS.ai
EVO NXT 2026 Opens in Prague as Global NGP Industry Gathers for Two-Day Event
EVO NXT 2026 Opens in Prague as Global NGP Industry Gathers for Two-Day Event
2026 — EVO NXT 2026 officially opened today in Prague, bringing together manufacturers, brand owners, retailers, and decision-makers from across the global next-generation products (NGP) industry. As the event’s official media partner for the fourth consecutive year, 2Firsts is reporting on site, tracking key developments across the exhibition floor, forum agenda, and broader industry discussions.
Apr.17 by 2FIRSTS.ai
BAT New Zealand Says Illicit Tobacco Trade Drove Nearly 29% Revenue Decline in 2025
BAT New Zealand Says Illicit Tobacco Trade Drove Nearly 29% Revenue Decline in 2025
British American Tobacco New Zealand said the illicit tobacco trade is responsible for its profit halving and revenue falling between the 2024 and 2025 financial years. Financial results filed with the Companies Office show that BAT Holdings (New Zealand) recorded 2025 revenue of NZ$180.7 million, or about US$106.95 million based on the European Central Bank’s April 27, 2026 reference rates, down from NZ$254 million, or about US$150.33 million, in 2024.
Apr.28 by 2FIRSTS.ai
FDA Launches Elsa 4.0 and Completes HALO Data Platform Consolidation
FDA Launches Elsa 4.0 and Completes HALO Data Platform Consolidation
The U.S. Food and Drug Administration announced on May 6 that it has advanced its modernization initiative by launching Elsa 4.0, an upgraded internal AI tool, and consolidating more than 40 application and submission data sources, systems and portals into a new platform called HALO. FDA said the integration of HALO and Elsa will allow staff to query data and build workflows without manually uploading documents in each chat.
May.07 by 2FIRSTS.ai
From Heating Blades to Heating Paper? CTHB Patent Points to Microwave Heated Tobacco Design
From Heating Blades to Heating Paper? CTHB Patent Points to Microwave Heated Tobacco Design
According to China’s patent office records, a patent owned by China Tobacco Hubei Industrial Corporation (CTHB) for “cigarette paper and a cigarette for microwave heating” was granted on May 19, 2026. The patent describes cigarette paper with an outer wrapping layer, a heating layer, and an isolation heat-conducting layer, allowing it to absorb microwave energy, convert it to heat, and transfer that heat to the aerosol-generating substrate.
Jun.10
Glas Says FDA Scientific Review Backed Several Flavored Products Before Senior Leaders Blocked Them
Glas Says FDA Scientific Review Backed Several Flavored Products Before Senior Leaders Blocked Them
Glas says newly released internal FDA records show agency scientific reviewers supported authorization for several flavored G2 products before senior leadership halted them. According to documents obtained through a Freedom of Information Act request, FDA’s Office of Science first recommended marketing authorization for all eight products in December 2025 and later supported six of them in February 2026. FDA ultimately authorized only the G2 device and one tobacco-flavored pod in March.
Apr.23 by 2FIRSTS.ai